Nadav Kidron - 22 Jan 2026 Form 4 Insider Report for ORAMED PHARMACEUTICALS INC. (ORMP)

Reporting relationship: President and CEO, Director
Issuer ticker: ORMP
Reported as of: 22 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Jan 2026, 16:05:30 UTC
Prior SEC filing: 05 Jan 2026
Next SEC filing: 16 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Nadav Kidron

Key filing fact

Nadav Kidron filed Form 4 for ORAMED PHARMACEUTICALS INC. (ORMP) on 29 Jan 2026.

Key facts

This page summarizes Nadav Kidron's Form 4 filing for ORAMED PHARMACEUTICALS INC. (ORMP).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 29 Jan 2026, 16:05.

Change

Previous filing in this sequence was filed on 05 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001351779 Primary reporting owner

KIDRON NADAV

Relationship: President and CEO, Director
Address: 1185 AVENUE OF THE AMERICAS, THIRD FLOOR, NEW YORK
Signature: /s/ Nadav Kidron
Signature date: 29 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ORMP transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +109,000
Change %: +3.4%
Price: $0.000000
Shares after: 3,355,238
Date: 22 Jan 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ORMP transaction Derivative

Performance Stock Units

Options Exercise

Transaction value: $0
Shares: -109,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 22 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 109,000
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting.

Footnote F2

Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria.